Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manlio Fusciello

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Human Gene Therapy|September 12, 2023
Personalizing Oncolytic VirotherapyFiras Hamdan, Manlio Fusciello, Vincenzo Cerullo
Advances in Experimental Medicine and Biology|February 5, 2021
Viral Nanoparticles: Cancer Vaccines and Immune ModulatorsManlio Fusciello, Erkko Ylösmäki, Vincenzo Cerullo
Journal for Immunotherapy of Cancer|July 12, 2019
Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor siteAlessandra Lopes, Sara Feola, Sophie Ligot, et al.
Molecular Therapy. Methods & Clinical Development|February 19, 2025
An automated and high-throughput approach for enhanced precision of adenoviral titeringPaolo Bottega, Manlio Fusciello, Firas Hamdan, et al.
Plos One|October 24, 2019
Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapyLeena Ylösmäki, Beatrice Polini, Sara Carpi, et al.
Molecular Therapy Oncolytics|May 16, 2022
A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubellaManlio Fusciello, Erkko Ylösmäki, Sara Feola, et al.
Molecular Therapy. Methods & Clinical Development|March 15, 2021
GAMER-Ad: a novel and rapid method for generating recombinant adenovirusesFiras Hamdan, Beatriz Martins, Michaela Feodoroff, et al.
Molecular Therapy Oncolytics|March 13, 2023
Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenovirusesFiras Hamdan, Michaela Feodoroff, Salvatore Russo, et al.
Journal for Immunotherapy of Cancer|July 16, 2021
Novel personalized cancer vaccine platform based on Bacillus Calmette-GuèrinErkko Ylösmäki, Manlio Fusciello, Beatriz Martins, et al.
Oncoimmunology|September 22, 2017
A novel <i>in silico</i> framework to improve MHC-I epitopes and break the tolerance to melanomaCristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Human Gene Therapy|September 12, 2023
Personalizing Oncolytic VirotherapyFiras Hamdan, Manlio Fusciello, Vincenzo Cerullo
Advances in Experimental Medicine and Biology|February 5, 2021
Viral Nanoparticles: Cancer Vaccines and Immune ModulatorsManlio Fusciello, Erkko Ylösmäki, Vincenzo Cerullo
Journal for Immunotherapy of Cancer|July 12, 2019
Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor siteAlessandra Lopes, Sara Feola, Sophie Ligot, et al.
Molecular Therapy. Methods & Clinical Development|February 19, 2025
An automated and high-throughput approach for enhanced precision of adenoviral titeringPaolo Bottega, Manlio Fusciello, Firas Hamdan, et al.
Plos One|October 24, 2019
Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapyLeena Ylösmäki, Beatrice Polini, Sara Carpi, et al.
Molecular Therapy Oncolytics|May 16, 2022
A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubellaManlio Fusciello, Erkko Ylösmäki, Sara Feola, et al.
Molecular Therapy. Methods & Clinical Development|March 15, 2021
GAMER-Ad: a novel and rapid method for generating recombinant adenovirusesFiras Hamdan, Beatriz Martins, Michaela Feodoroff, et al.
Molecular Therapy Oncolytics|March 13, 2023
Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenovirusesFiras Hamdan, Michaela Feodoroff, Salvatore Russo, et al.
Journal for Immunotherapy of Cancer|July 16, 2021
Novel personalized cancer vaccine platform based on Bacillus Calmette-GuèrinErkko Ylösmäki, Manlio Fusciello, Beatriz Martins, et al.
Oncoimmunology|September 22, 2017
A novel <i>in silico</i> framework to improve MHC-I epitopes and break the tolerance to melanomaCristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, et al.
Pageof 4